(Q52927812)

9 May 2018

title

Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial. (English)

1 reference

9 May 2018

main subject

phase III clinical trial

0 references

phase II clinical trial

0 references

author name string

J A Tavel

series ordinal

1

1 reference

9 May 2018

L Fosdick

series ordinal

2

1 reference

9 May 2018

ESPRIT Vanguard Group. ESPRIT Executive Committee

series ordinal

3

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 February 2001

1 reference

9 May 2018

Contemporary Clinical Trials

published in

1 reference

9 May 2018

volume

22

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

page(s)

42-48

1 reference

9 May 2018

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

Ambitious clinical trial stirs debate

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

Thirty years of Medical Research Council randomized trials in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900114-8

7 January 2021

10.1016/S0197-2456(00)00114-8

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018